Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LXRX
- Price
- 0.53
- Stock movement up
- +0.02 (3.56%)
- Company name
- Lexicon Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 191.59M
- Ent value
- 299.65M
- Price/Sales
- 36.64
- Price/Book
- 1.07
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -6.80%
- 1 year return
- -73.89%
- 3 year return
- -41.81%
- 5 year return
- -21.87%
- 10 year return
- -22.17%
Last updated: 2025-04-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
LXRX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 36.64 |
| Price to Book | 1.07 |
| EV to Sales | 57.31 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 361.49M |
| EPS (TTM) | -0.59 |
| FCF per share (TTM) | -0.58 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 5.23M |
| Gross profit (TTM) | 4.60M |
| Operating income (TTM) | -211.12M |
| Net income (TTM) | -214.88M |
| EPS (TTM) | -0.59 |
| EPS (1y forward) | -0.49 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.97% |
| Operating margin (TTM) | -4037.43% |
| Profit margin (TTM) | -4109.41% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 34.55M |
| Net receivables | 2.90M |
| Total current assets | 268.61M |
| Goodwill | 44.54M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 9.11M |
| Total assets | 321.12M |
| Accounts payable | 14.20M |
| Short/Current long term debt | 101.20M |
| Total current liabilities | 36.05M |
| Total liabilities | 142.61M |
| Shareholder's equity | 178.51M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -207.84M |
| Capital expenditures (TTM) | 557.00K |
| Free cash flow (TTM) | -208.39M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -120.37% |
| Return on Assets | -66.92% |
| Return on Invested Capital | -76.82% |
| Cash Return on Invested Capital | -74.50% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.53 |
| Daily high | 0.60 |
| Daily low | 0.52 |
| Daily Volume | 7.77M |
| All-time high | 329.88 |
| 1y analyst estimate | 3.60 |
| Beta | 1.24 |
| EPS (TTM) | -0.59 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 30 Apr 2025 |
Downside potential
Loading...
Downside potential data
| LXRX | S&P500 | |
| Current price drop from All-time high | -99.84% | -12.04% |
| Highest price drop | -99.91% | -56.47% |
| Date of highest drop | 3 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -92.85% | -11.07% |
| Avg time to new high | 449 days | 12 days |
| Max time to new high | 6219 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
191.59M
Marketcap category
Small-cap
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Employees
285
Website
Investor relations
-
SEC filings
CEO
Lonnel Coats
Country
USA
City
The Woodlands
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page